Virginia Health Clinic Provides Blueprint for Treating Local HCV Patients with Substance History
A Lynchburg-based clinic was able to cure hepatitis C in all follow-through patients with substance abuse who underwent a comprehensive care plan over 8 weeks.
Read More
Needle Stick Injuries Common Among Health Care Workers Not Fully Vaccinated for HBV
A study from Nepal showed a majority of teaching hospital health providers were accidentally exposed to needles. The group additionally had limited knowledge of their HBV vaccination status.
Preference for an Alternative to Colonoscopies Growing in the US
New data from the CONFIRM trial show the noninvasive FIT testing method is increasing in preference over colonoscopy by about 20% annually.
Type 2 Diabetes Increases Liver Decompensation, Cancer Risk in NAFLD Patients
A meta-analysis shows patients with both NAFLD and type 2 diabetes are at significantly greater risk of hepatic decompensation and HCC over a 5-year span.
HCV Antivirals May Improve Hepatocellular Carcinoma Survival Rates
Direct-acting antivirals or interferon may improve the rate of overall or recurrence-free survival for patients with liver cancer.
Fecal Incontinence is Highly Associated with IBS or Constipation
A cross-sectional analysis from China suggests approximately 1 in 10 individuals suffer from incontinence, though not all are seeking adequate care or specialist consultation.
Investigative Celiac Disease Drug KAN-101 Safe, Tolerable in Phase 1 Study
Early-stage data support KAN-101, a liver-targeting drug that's vying to become the first treatment approved to treat celiac disease.
Two-Thirds of Americans with Hepatitis C Have not Cleared Disease
A cascade-of-clearance study from the CDC shows the country is far from its goal of eliminating 80% of hepatitis C cases by 2030.
6 FDA Decisions Expected Before 2024
From a novel acne cream to a breakthrough depression drug, a half-dozen agent decisions are coming through in the coming 6 months.
Microencapsulated Benzoyl Peroxide Rapidly, Significant Improves Rosacea
Analysis of a novel form of the topical drug shows rosacea is benefitted within 2 weeks of daily administration.
Ixekizumab Linked to Low Risk of Major Cardiovascular Events in Psoriatic Patients
An analysis of patients with psoriasis, PsA, or axSpA show risk of MACE with ixekizumab is consistently low.
FDA Issues Complete Response Letter for Aflibercept 8 mg as AMD, DME Treatment
The letter makes reference to an ongoing review of inspection findings from a third-party filler involved with the drug development. Regeneron will not require additional trial data.
FDA Approves Ritlecitinib as First Drug for Adolescent Alopecia Areata
Ritlecitinib becomes the second JAK inhibitor approved to treat alopecia—and the first to be indicated for patients aged 12 years and older.
Tazarotene Lotion Benefit for Acne Does Not Differ by Season
Post hoc analysis of the topical therapy show patients receiving treatment for acne in the winter were as likely to achieve benefit as those receiving it in the summer.
Secukinumab Significantly Improves Hindradenitis Suppurativa Regardless of Demographics
A post hoc analysis of phase 3 adds support to the IL-17A inhibitor for the potential treatment of HS.
Dawn Eichenfield, MD: Identifying Allergies in Pediatric Dermatology
While contact dermatitis is difficult to distinguish in children, there has become a greater collaboration between allergic and dermatologic specialists in managing conditions like atopic dermatitis.
Hilary Baldwin, MD: IDP-126 May Change Acne Management
The first triple-combination topical drug for acne may be available by the end of this year. One expert has high hopes for it.
Matthew Zirwas, MD: Ruxolitinib Cream and the Eczema JAK Inhibitor Era
Zirwas touts topical ruxolitinib's rapid, effective treatment of atopic dermatitis, and reviews the safety outcomes associated with JAK inhibitors.
Amit Pandya, MD: The Discovery of Oral Tranexamic Acid for Melasma
Pigmentary disorders including melasma are difficult to treat and complex. The leading agent for one expert was uncovered by unique circumstances.
Dawn Eichenfield, MD: Tips for Managing Severe Acne
From addressing the rare acne fulminans to utilizing narrow-spectrum antibiotics, the modern field of acne treatment is more complicated than it seems.
Baricitinib Consistently Safe, Tolerable for Severe Alopecia Areata at 2 Years
Analysis of phase 3 trial data show the JAK inhibitor is generally safe among patients with severe forms of the chronic hair loss disease.
Hilary Baldwin, MD: The Surge of Rosacea Treatment Options
In the span of a decade, agents like topical ivermectin, minocycline and benzoyl peroxide has provided more opportunities to achieve clear skin for rosacea patients.
Amit Pandya, MD: Ruxolitinib Cream in Real-World Vitiligo Patients of Color
The trial investigator reviews disparities in patient needs and treatment outcomes based on their skin complexion, 1 year after ruxolitinib's FDA approval.
Melodie Young, MSN, ANP-c: Managing Comorbid Psoriatic Disease
Often lost in the fray of new drug development is the need to reinforce improved behavioral health, explains a longtime dermatology nurse practitioner.
Matthew Zirwas, MD: How Tapinarof Could Address Adult-Onset Atopic Dermatitis
On the basis of discovery into what drives adult-onset eczema, the novel drug may provide a unique benefit for impacted patients.
Nemolizumab Rapidly Improves EASI, SCORAD Scores for Atopic Dermatitis
A post hoc analysis shows the investigative drug significantly improved atopic dermatitis symptoms versus placebo as soon as the first week into a phase 2 trial.
Melodie Young, MSN, ANP-c: Keeping up with Dermatology's Advances
It's been a whirlwind few years for dermatology. The nurse practitioner discusses modern care teams, comorbid psoriatic disease, and expanding patient inclusion in clinical trials.
Albert Yan, MD: Navigating Advances to Acne Therapies, Monitoring
Yan discusses how acne care strategies have been bolstered—and complicated—by pharmacotherapy and telemedicine developments.
Matthew Zirwas, MD: How Do Emerging HS Treatments Line Up?
With multiple drug classes working toward FDA indication, a dermatologists explains his strategy for managing hidradenitis suppurativa.
Tapinarof Cream Tolerable, Safe in Pediatric Patients with Atopic Dermatitis
The first trial observing the topical drug in children held promise for an extended indication.